These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 15039594)

  • 1. Validation of a tissue microarray to study differential protein expression in inflammatory and non-inflammatory breast cancer.
    Van den Eynden GG; Van der Auwera I; Van Laere S; Colpaert CG; van Dam P; Merajver S; Kleer CG; Harris AL; Van Marck EA; Dirix LY; Vermeulen PB
    Breast Cancer Res Treat; 2004 May; 85(1):13-22. PubMed ID: 15039594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer.
    Van den Eynden GG; Van Laere SJ; Van der Auwera I; Merajver SD; Van Marck EA; van Dam P; Vermeulen PB; Dirix LY; van Golen KL
    Breast Cancer Res Treat; 2006 Feb; 95(3):219-28. PubMed ID: 16244790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistent E-cadherin expression in inflammatory breast cancer.
    Kleer CG; van Golen KL; Braun T; Merajver SD
    Mod Pathol; 2001 May; 14(5):458-64. PubMed ID: 11353057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding.
    Van Laere SJ; Van der Auwera I; Van den Eynden GG; Elst HJ; Weyler J; Harris AL; van Dam P; Van Marck EA; Vermeulen PB; Dirix LY
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3249-56. PubMed ID: 16740744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'.
    Charafe-Jauffret E; Tarpin C; Bardou VJ; Bertucci F; Ginestier C; Braud AC; Puig B; Geneix J; Hassoun J; Birnbaum D; Jacquemier J; Viens P
    J Pathol; 2004 Mar; 202(3):265-73. PubMed ID: 14991891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis.
    Van Laere S; Van der Auwera I; Van den Eynden GG; Fox SB; Bianchi F; Harris AL; van Dam P; Van Marck EA; Vermeulen PB; Dirix LY
    Breast Cancer Res Treat; 2005 Oct; 93(3):237-46. PubMed ID: 16172796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [High-throughput quantification of tissue microarrays: identification of candidate target proteins in inflammatory breast cancer].
    Taranger-Charpin C; Andrac-Meyer L; Dales JP; Carpentier-Meunier S; Andonian C; Lavaut MN; Allasia C; Bonnier P
    Bull Acad Natl Med; 2007 Feb; 191(2):361-74; discussion 374-6. PubMed ID: 17969554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct molecular phenotype of inflammatory breast cancer compared to non-inflammatory breast cancer using Affymetrix-based genome-wide gene-expression analysis.
    Van Laere S; Van der Auwera I; Van den Eynden G; Van Hummelen P; van Dam P; Van Marck E; Vermeulen PB; Dirix L
    Br J Cancer; 2007 Oct; 97(8):1165-74. PubMed ID: 17848951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer.
    McCarthy NJ; Yang X; Linnoila IR; Merino MJ; Hewitt SM; Parr AL; Paik S; Steinberg SM; Hartmann DP; Mourali N; Levine PH; Swain SM
    Clin Cancer Res; 2002 Dec; 8(12):3857-62. PubMed ID: 12473600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast.
    Kleer CG; Griffith KA; Sabel MS; Gallagher G; van Golen KL; Wu ZF; Merajver SD
    Breast Cancer Res Treat; 2005 Sep; 93(2):101-10. PubMed ID: 16187229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype.
    Nguyen DM; Sam K; Tsimelzon A; Li X; Wong H; Mohsin S; Clark GM; Hilsenbeck SG; Elledge RM; Allred DC; O'Connell P; Chang JC
    Clin Cancer Res; 2006 Sep; 12(17):5047-54. PubMed ID: 16951220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue microarray-based immunohistochemical study can significantly underestimate the expression of HER2 and progesterone receptor in ductal carcinoma in situ of the breast.
    Lin Y; Hatem J; Wang J; Quinn A; Hicks D; Tang P
    Biotech Histochem; 2011 Oct; 86(5):345-50. PubMed ID: 20701550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. c-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarrays.
    Garcia S; Dalès JP; Jacquemier J; Charafe-Jauffret E; Birnbaum D; Andrac-Meyer L; Lavaut MN; Allasia C; Carpentier-Meunier S; Bonnier P; Charpin-Taranger C
    Br J Cancer; 2007 Jan; 96(2):329-35. PubMed ID: 17242702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype.
    van Golen KL; Wu ZF; Qiao XT; Bao LW; Merajver SD
    Cancer Res; 2000 Oct; 60(20):5832-8. PubMed ID: 11059780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling.
    Van Laere SJ; Van den Eynden GG; Van der Auwera I; Vandenberghe M; van Dam P; Van Marck EA; van Golen KL; Vermeulen PB; Dirix LY
    Breast Cancer Res Treat; 2006 Feb; 95(3):243-55. PubMed ID: 16261404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.
    Johnston S; Trudeau M; Kaufman B; Boussen H; Blackwell K; LoRusso P; Lombardi DP; Ben Ahmed S; Citrin DL; DeSilvio ML; Harris J; Westlund RE; Salazar V; Zaks TZ; Spector NL
    J Clin Oncol; 2008 Mar; 26(7):1066-72. PubMed ID: 18212337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer.
    Zhang D; Salto-Tellez M; Putti TC; Do E; Koay ES
    Mod Pathol; 2003 Jan; 16(1):79-84. PubMed ID: 12527717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical COX-2 overexpression correlates with HER-2/neu overexpression in invasive breast carcinomas: a pilot study.
    Çiriş IM; Bozkurt KK; Başpinar S; Kapucuoğlu FN
    Pathol Res Pract; 2011 Mar; 207(3):182-7. PubMed ID: 21371829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammatory breast cancers in Tunisia and France show similar immunophenotypes.
    Charafe-Jauffret E; Mrad K; Intidhar Labidi S; Ben Hamida A; Ben Romdhane K; Ben Abdallah M; Ginestier C; Esterni B; Birnbaum D; Ben Ayed F; Xerri L; Viens P; Mezlini A; Jacquemier J
    Breast; 2007 Aug; 16(4):352-8. PubMed ID: 17360185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative analysis of breast cancer tissue microarrays shows high cox-2 expression is associated with poor outcome.
    Zerkowski MP; Camp RL; Burtness BA; Rimm DL; Chung GG
    Cancer Invest; 2007 Feb; 25(1):19-26. PubMed ID: 17364553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.